ArticleHematology, transfusion and cell therapy2026
Are quality of life data reported in clinical trials evaluating CAR T cells in hematologic malignancies?
Article in Hematology, transfusion and cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIncreasing indications for CAR T cells in early-line hematological malignancies underscore the need to report patient experiences. However, data regarding patient quality of life in this setting remain limited.
objectiveThis study aimed to assess the inclusion of Health-Related Quality of Life as an endpoint in clinical trials registered on ClinicalTrials.gov for CAR T-cell therapies in hematological malignancies.
methodsA comprehensive search of the U.S. National Institutes of Health database (ClinicalTrials.gov) was performed for trials registered up to August 28, 2022, using the keywords "CAR" AND ("lymphoma" OR "multiple myeloma" OR "leukemia" OR "hematologic malignancy"). For each selected trial, data regarding study design, setting, indication, treatment line, relevant outcomes, and evaluation scales were collected. MAIN
resultsOut of 1281 records, 429 trials met the inclusion criteria and were analyzed, with over half being phase 1. The most common primary endpoint was safety (47%). Health-Related Quality of Life was assessed as a secondary endpoint in only 11% of trials. A wide variety of questionnaires were identified, and data collection methodologies (baseline assessments, timepoints, and follow-up duration) varied considerably across studies.
conclusionEstablishing a standardized consensus for measuring Health-Related Quality of Life is essential to complement efficacy data in clinical trials and real-world studies evaluating CAR T-cell therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.